Goldman Sachs analyst Paul Choi initiated coverage of Entrada Therapeutics (TRDA) with an Early-Stage Biotech designation, saying the company’s Endosomal Escape Vehicle platform is differentiated from other delivery peptide approaches. It sees “best-in-class potential.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics price target lowered to $17 from $21 at Roth Capital
- Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements
- Entrada Therapeutics Reports Q2 2025 Financial Results
- Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics
- Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)